



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

## \*CORRESPONDENCE

Christopher D. Anderson  
✉ cdanderson@mgb.org  
Guido J. Falcone  
✉ guido.falcone@yale.edu

## †PRESENT ADDRESS

Keren Papier,  
Cancer Epidemiology Unit, Nuffield  
Department of Population Health, Oxford,  
United Kingdom

†These authors have contributed equally to  
this work

RECEIVED 25 October 2024

ACCEPTED 30 October 2024

PUBLISHED 12 November 2024

## CITATION

Singh SD, Rivier CA, Papier K, Chemali Z,  
Gutierrez-Martinez L, Parodi L, Mayerhofer E,  
Senff J, Clocchiatti-Tuozzo S, Nunley C,  
Newhouse A, Ouyang A, Westover MB,  
Tanzi RE, Lazar RM, Pikula A, Ibrahim S,  
Brouwers HB, Howard VJ, Howard G,  
Yecheor N, Littlejohns T, Sheth KN, Rosand J,  
Fricchione G, Anderson CD and Falcone GJ  
(2024) Corrigendum: The predictive validity  
of a Brain Care Score for late-life depression  
and a composite outcome of dementia,  
stroke, and late-life depression: data from  
the UK Biobank cohort.  
*Front. Psychiatry* 15:1502482.  
doi: 10.3389/fpsy.2024.1502482

## COPYRIGHT

© 2024 Singh, Rivier, Papier, Chemali,  
Gutierrez-Martinez, Parodi, Mayerhofer, Senff,  
Clocchiatti-Tuozzo, Nunley, Newhouse,  
Ouyang, Westover, Tanzi, Lazar, Pikula, Ibrahim,  
Brouwers, Howard, Howard, Yecheor,  
Littlejohns, Sheth, Rosand, Fricchione,  
Anderson and Falcone. This is an open-access  
article distributed under the terms of the  
[Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/).  
The use, distribution or reproduction in other  
forums is permitted, provided the original  
author(s) and the copyright owner(s) are  
credited and that the original publication in  
this journal is cited, in accordance with  
accepted academic practice. No use,  
distribution or reproduction is permitted  
which does not comply with these terms.

# Corrigendum: The predictive validity of a Brain Care Score for late-life depression and a composite outcome of dementia, stroke, and late-life depression: data from the UK Biobank cohort

Sanjula D. Singh<sup>1,2,3†</sup>, Cyprien A. Rivier<sup>4,5†</sup>, Keren Papier<sup>6†</sup>,  
Zeina Chemali<sup>1,2,7</sup>, Leidys Gutierrez-Martinez<sup>1,2,3</sup>,  
Livia Parodi<sup>1,2,3,8,9</sup>, Ernst Mayerhofer<sup>1,2,3,8,9</sup>, Jasper Senff<sup>1,2,3,10</sup>,  
Santiago Clocchiatti-Tuozzo<sup>4,5</sup>, Courtney Nunley<sup>1</sup>,  
Amy Newhouse<sup>1,7,11</sup>, An Ouyang<sup>1</sup>, M. Brandon Westover<sup>1,2</sup>,  
Rudolph E. Tanzi<sup>1,2</sup>, Ronald M. Lazar<sup>12</sup>, Aleksandra Pikula<sup>13,14</sup>,  
Sarah Ibrahim<sup>13,15,16,17</sup>, H. Bart Brouwers<sup>18</sup>, Virginia J. Howard<sup>19</sup>,  
George Howard<sup>19</sup>, Nirupama Yecheor<sup>1,2,3</sup>, Thomas Littlejohns<sup>6</sup>,  
Kevin N. Sheth<sup>4,5</sup>, Jonathan Rosand<sup>1,2,3,8</sup>, Gregory Fricchione<sup>1,20</sup>,  
Christopher D. Anderson<sup>1,2,3,8,9\*†</sup> and Guido J. Falcone<sup>4,5\*†</sup>

<sup>1</sup>Henry and Allison McCance Center for Brain Health, Massachusetts General Hospital, Boston, MA, United States, <sup>2</sup>Department of Neurology, Massachusetts General Hospital, Boston, MA, United States, <sup>3</sup>Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, United States, <sup>4</sup>Department of Neurology, Yale School of Medicine, New Haven, CT, United States, <sup>5</sup>Yale Center for Brain and Mind Health, New Haven, CT, United States, <sup>6</sup>Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom, <sup>7</sup>Division of Neuropsychiatry, Massachusetts General Hospital, Boston, MA, United States, <sup>8</sup>Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, United States, <sup>9</sup>Department of Neurology, Brigham and Women's Hospital, Boston, MA, United States, <sup>10</sup>Department of Neurology, Rudolf Magnus Institute of Neuroscience, University Medical Centre Utrecht, Utrecht, Netherlands, <sup>11</sup>Department of Medicine, Massachusetts General Hospital, Boston, MA, United States, <sup>12</sup>Department of Neurology, University of Alabama at Birmingham (UAB) Heersink School of Medicine, University of Alabama at Birmingham (UAB) McKnight Brain Institute, Birmingham, AL, United States, <sup>13</sup>Jay and Sari Sonshine Centre for Stroke Prevention & Cerebrovascular Brain Health, University Health Network, Krembil Brain Institute, Toronto, ON, Canada, <sup>14</sup>Department of Medicine, Division of Neurology, The Temerty Faculty of Medicine at the University of Toronto, Toronto, ON, Canada, <sup>15</sup>Program for Health System and Technology Evaluation; Toronto General Hospital Research Institute, Toronto, ON, Canada, <sup>16</sup>Institute of Health Policy, Management and Evaluation (IHPE), Dalla Lana School of Public Health; University of Toronto, Toronto, ON, Canada, <sup>17</sup>Centre for Advancing Collaborative Healthcare & Education (CACHE), University of Toronto, Toronto, ON, Canada, <sup>18</sup>Department of Neurosurgery, Elisabeth TweeSteden Ziekenhuis, Tilburg, Netherlands, <sup>19</sup>Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, United States, <sup>20</sup>Benson-Henry Institute for Mind Body Medicine, Massachusetts General Hospital, Boston, MA, United States

## KEYWORDS

depression - epidemiology, prevention, risk factor, brain health, stroke, dementia

### A Corrigendum on

#### The predictive validity of a Brain Care Score for late-life depression and a composite outcome of dementia, stroke, and late-life depression: data from the UK Biobank cohort

By Singh SD, Rivier CA, Papier K, Chemali Z, Gutierrez-Martinez L, Parodi L, Mayerhofer E, Senff J, Clocchiatti-Tuozzo S, Nunley C, Newhouse A, Ouyang A, Westover MB, Tanzi RE, Lazar RM, Pikula A, Ibrahim S, Brouwers HB, Howard VJ, Howard G, Yechoor N, Littlejohns T, Sheth KN, Rosand J, Fricchione G, Anderson CD and Falcone GJ (2024) *Front. Psychiatry* 15:1373797. doi: 10.3389/fpsy.2024.1373797

In the published article there was a error in the **Conflict of interest** statement for M. Brandon Westover. The statement was previously:

“CA receives sponsored research support from the US National Institutes of Health, the American Heart Association, and Bayer AG, and has consulted for ApoPharma. GF receives sponsored research support from the National Institute of Mental Health Clinical Global Mental Health Research T32 Fellowship, receives royalties or licenses from Johns Hopkins University Press, University of Chicago Press, Belvoir Press, and the American Psychiatric Press, is on a Data Safety Monitoring Board or Advisory Board of Healthy Hearts Healthy Minds DSMB, is a Board of Directors member at the Rosalynn Carter Institute, and has stock or stock options from Revival Therapeutics Consultant. LG-M receives sponsored research support from the American Heart grant number 963719. JR receives sponsored research support from the US National Institutes of Health and the American Heart Association, and receives payments for expert testimony and consulting fees from the National Football League. EM is an employee of Regeneron Genetics Center.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of *Frontiers*, at the time of submission. This had no impact on the peer review process and the final decision.”

The correct statement appears below:

“CA receives sponsored research support from the US National Institutes of Health, the American Heart Association, and Bayer AG, and has consulted for ApoPharma. GF receives sponsored research support from the National Institute of Mental Health Clinical Global Mental Health Research T32 Fellowship, receives royalties or licenses from Johns Hopkins University Press,

University of Chicago Press, Belvoir Press, and the American Psychiatric Press, is on a Data Safety Monitoring Board or Advisory Board of Healthy Hearts Healthy Minds DSMB, is a Board of Directors member at the Rosalynn Carter Institute, and has stock or stock options from Revival Therapeutics Consultant. LG-M receives sponsored research support from the American Heart grant number 963719. JR receives sponsored research support from the US National Institutes of Health and the American Heart Association, and receives payments for expert testimony and consulting fees from the National Football League. EM is an employee of Regeneron Genetics Center. MW has private equity as co-founder of Beacon Biosignals and receives compensation for consulting and scientific advisory roles.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of *Frontiers*, at the time of submission. This had no impact on the peer review process and the final decision.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

### Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.